Sulfotransferase 4A1 haplotype 1 (SULT4A1-1) is associated with decreased hospitalization events in antipsychotic-treated patients with Schizophrenia

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 3, 2012, Pages

  Liu, Qian ^a   Ramsey, Timothy L ^a   Meltzer, Herbert Y ^b   Massey, Bill W ^a   Padmanabhan, Saranya ^a   Brennan, Mark D ^a  

^a SureGene LLC   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; GENE; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HAZARD ASSESSMENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTION; RISK ASSESSMENT; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SULFOTRANSFERASE 4A1 1 GENE; TREATMENT DURATION;

EID: 84864702490     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11m01293     Document Type: Article

References (19)

1. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419-429. PubMed Show Abstract Show Abstract
2. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122-1129. PubMed doi:10.4088/JCP.v66n0906 Show Abstract Show Abstract
3. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10(1):2. PubMed doi:10.1186/1471-244X-10-2 Show Abstract Show Abstract
4. Vasudeva S, Narendra Kumar MS, Sekhar KC. Duration of first admission and its relation to the readmission rate in a psychiatry hospital. Indian J Psychiatry. 2009;51(4):280-284. PubMed doi:10.4103/0019-5545.58294 Show Abstract Show Abstract
5. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7(1):4. PubMed doi:10.1186/1478-7547-7-4 Show Abstract Show Abstract
6. Meltzer HY, Brennan MD, Woodward ND, et al. Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2008;106(2-3):258-264. PubMed doi:10.1016/j.schres.2008.08.029 Show Abstract Show Abstract
7. Ramsey TL, Meltzer HY, Brock GN, et al. Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics. 2011;12(4):471-480. PubMed doi:10.2217/pgs.10.205 Show Abstract Show Abstract
8. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. PubMed doi:10.1056/NEJMoa051688 Show Abstract Show Abstract
9. Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008;13(6):570-584. PubMed doi:10.1038/mp.2008.25 Show Abstract Show Abstract
10. Need AC, Keefe RS, Ge D, et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet. 2009;17(7):946-957. PubMed doi:10.1038/ejhg.2008.264 Show Abstract Show Abstract
11. van den Oord EJ, Adkins DE, McClay J, et al. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res. 2009;107(1):13-21. PubMed doi:10.1016/j.schres.2008.09.009 Show Abstract Show Abstract
12. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology. 2011;36(3):616-626. PubMed doi:10.1038/npp.2010.193 Show Abstract Show Abstract
13. Center for Collaborative Genomic Studies on Mental Disorders Web site. https://www.nimhgenetics.org/. Accessed March 14, 2012.
14. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;184(408):1074-1078. doi:10.2307/2290085
15. Bigos KL, Bies RR, Pollock BG, et al. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry. 2011;16(6):620-625. PubMed doi:10.1038/mp.2011.38 Show Abstract Show Abstract
16. Liyou NE, Buller KM, Tresillian MJ, et al. Localization of a brain sulfotransferase, SULT4A1, in the human and rat brain: an immunohistochemical study. J Histochem Cytochem. 2003;51(12):1655-1664. PubMed doi:10.1177/002215540305101209 Show Abstract Show Abstract
17. Allali-Hassani A, Pan PW, Dombrovski L, et al. Structural and chemical profiling of the human cytosolic sulfotransferases. PLoS Biol. 2007;5(5):e97. PubMed doi:10.1371/journal.pbio.0050097 Show Abstract Show Abstract
18. Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev. 2003;27(3):269-306. PubMed doi:10.1016/S0149-7634(03)00035-6 Show Abstract Show Abstract
19. Kazadi NJB, Moosa MYH, Jeenah FY. Factors associated with relapse in schizophrenia. South African J Psychiatry. 2008;14(2):52-62.